Google
ICLR 株価分析 — Icon PLC (Healthcare >> Diagnostics & Research)
ICLR に関するよくある質問
ICLRのPER（株価収益率）は？
Icon PLC（ICLR）は現在PER 71.08倍で取引されています。
ICLRのROE（自己資本利益率）は？
Icon PLCのROEは0.74%です。
ICLRの配当利回りは？
Icon PLCの配当利回りは0.00%です。
ICLRの品質スコア（Quality Score）は？
当社のAIはICLRの総合財務品質を100点中15点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
ICLRは今が買い時ですか？
当社AIのタイミングスコアは100点中91点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
ICLRはどのセクターに属しますか？
Icon PLCはHealthcare >> Diagnostics & Researchセクターに分類されます（NASDAQ市場）
ICLR AI Analysis Summary
Our AI summary for ICLR: Icon PLC (NASDAQ), Healthcare >> Diagnostics & Research sector. The stock currently trades at a P/E of 71.08, ROE of 0.74%, a dividend yield of 0.00%. Its financial Quality Score stands at 15/100 — fundamentals below the market average. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 163.57
Price
-1.97
(-1.19%)
Day Change
|
|
|---|
ICLR, ファンダメンタルスコアはnot good ( ファンダメンタル = 15) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/Eが高い。割高銘柄。
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
2926
|
| Magic Formula Rank by ROE |
2926
|
| Magic Formula Rank by ROIC |
2952
|
| Price | 163.57 |
| PBV / Sector |
1.36 / -29.69
GOOD
|
| Earning Per Share | 0.89 |
| PE / Sector |
71.08 / 48.18
|
| PEG or PE/Growth / Sector |
-10.69 / 1.64
|
| Average 1M Daily Value |
136.10 M
GREAT
|
| Average 1W Daily Value |
230.62 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
58% |
| ポイントになる統計 |
|
50% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 07:59:59 |
| Symbol | ICLR |
| Name | ICON PLC |
| Sector | Healthcare >> Diagnostics & Research |
| Market | NASDAQ |
| Listed Shares | 77.15 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 12,771.34 / 38,081.42 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: South County Business Park, Dublin, Ireland, D18 X5R3
Phone: 353 1 291 2000
Website: https://www.iconplc.com
Employees: 40,350
Description: ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, contract staffing, data solutions, and laboratory services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers testing services comprising bioanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, medical imaging, real world intelligence, site and patient, and strategic solutions. Additionally, it provides therapeutics for cardiovascular, central nervous system, endocrine and metabolic disorders, hepatology, infectious diseases, internal medicine immunology, and oncology. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Diagnostics & Research
Click a bubble to view stock details · Bubble size represents market capitalization share
